PDF《2016》

Young Certified Public Accountants STOCK CODE ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED

6833 COMPANY WEBSITE www.sinco-pharm.com LISTING DATE

10 March

2016 公司总部 中国 四川省 成都市高新区 天府大道北段1700号 环球中心E5-1805室 香港主要营业地点 香港 皇后大道中183号 中远大厦44楼4408A室 开曼群岛证券登记总处及过户代理 Maples Fund Services (Cayman) Limited P.O. Box 1093, Boundary Hall Cricket Square Grand Cayman, KY1-1102 Cayman Islands 香港证券登记分处 香港中央证券登记有限公司 香港 湾仔 皇后大道东183号 合和中心17楼1712至1716室 香港法律顾问 美国谢尔曼 ? 思特灵律师事务所 核数师 安永会计师事务所 执业会计师 香港联合交易所有限公司 主板股份代号

6833 公司网站 www.sinco-pharm.com 上市日期 2016年3月10日Financial Highlights 财务摘要

4 Sinco Pharmaceuticals Holdings Limited Interim Report

2016 ? Revenue of the Group decreased by 6.5% to RMB569.4 million for the Reporting Period (six months ended

30 June 2015: RMB608.7 million), primarily due to the decrease in sales of Human Albumin Solution of RMB81.4 million, partially offset by the increase in sales of antibiotics and other products of RMB42.1 million. ? Gross profit of the Group increased by 0.5% to RMB83.1 million for the Reporting Period (six months ended

30 June 2015: RMB82.7 million), mainly due to the decrease in average purchase price of antibiotics and the increase in sales volume of other products with relatively higher gross profit margin. ? Net profit of the Group decreased by 37.4% to RMB30.5 million for the Reporting Period (six months ended

30 June 2015: RMB48.7 million). Without the impact of listing expenses, the adjusted net profit of the Group decreased by 6.3% to RMB48.0 million for the Reporting Period (six months ended

30 June 2015: RMB51.2 million). ? Profit attributable to owners of the Company decreased by 36.3% to RMB31.0 million for the Reporting Period (six months ended

30 June 2015: RMB48.7 million). ? Basic earnings per share amounted to RMB0.021 for the Reporting Period (six months ended

30 June 2015: RMB0.041). ? The Directors have resolved to declare an interim dividend of HK$0.0033 per share (equivalent to RMB0.0028 per share) for the Reporting Period (six months ended

30 June 2015: not applicable). Six months ended

30 June 截至6月30日止六个月

2016 RMB'

000

2015 RMB'

000 人民币千元 人民币千元 (unaudited) (unaudited) (未经审核) (未经审核) Operating results 经营业绩 Revenue 收益 569,373 608,681 Gross profit 毛利 83,054 82,705 Profit before tax 除税前溢利 40,416 57,842 Profit for the period 期内溢利 30,546 48,699 Profit attributable to owners of the Company 本公司拥有人应占溢利 31,062 48,699 Profitability 盈利 Gross margin (%) 毛利率(%) 14.6% 13.6% Net profit margin (%) 纯利率(%) 5.4% 8.0% ? 报告期内,本集团的收益减少6.5%至人民币 569.4百万元 (截至2015年6月30日止六个月:人 民币608.7百万元) ,主要是由於人血白蛋白注射 液的销售额减少人民币81.4百万元所致,部分被 抗生素........